Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $113 to $110.
Citizens analyst Jonathan Wolleben maintains Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform and lowers the price target from $113 to $110.